Dr. Reddy's Launches Hepatitis E Vaccine, Tackling Major Health Threat

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorKavya Nair|Published at:
Dr. Reddy's Launches Hepatitis E Vaccine, Tackling Major Health Threat
Overview

Dr. Reddy's Laboratories has launched Hevaxin, India's first approved recombinant vaccine for Hepatitis E infection in adults. The DCGI-endorsed vaccine addresses a critical unmet medical need, as Hepatitis E is a significant cause of acute liver failure and mortality in India. The introduction supports the National Viral Hepatitis Control Programme, aiming to reduce disease burden and expand Dr. Reddy's preventive healthcare portfolio.

Dr. Reddy's Unveils Hevaxin for Hepatitis E Prevention

Dr. Reddy's Laboratories has introduced Hevaxin, a novel recombinant vaccine for the prevention of Hepatitis E virus (HEV) infection, marking a significant public health advancement in India. The vaccine received approval from the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65 years. Clinical trials have demonstrated its protective efficacy, ability to support long-lasting immunity, and an established safety and tolerability profile.

Addressing a Critical Public Health Gap

M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets) at Dr. Reddy's, stated, "The launch of Hevaxin is a significant step in reinforcing our commitment to preventive healthcare and advancing our vaccine portfolio." He emphasized that Hepatitis E poses a serious threat, particularly to patients with chronic liver disease, often leading to acute-on-chronic liver failure and high fatality rates. Hevaxin offers a first-in-class preventive option, addressing a critical unmet patient need.

Supporting National Health Initiatives

The introduction of Hevaxin is also set to bolster the National Viral Hepatitis Control Programme, a key initiative by the Ministry of Health and Family Welfare. This program aims to significantly reduce the morbidity and mortality associated with Hepatitis E across India. Dr. Reddy's has partnered with Shenzhen Mellow Hope Pharm and Urihk Pharmaceutical for the domestic marketing and distribution of the vaccine.

Global and National Disease Burden

Globally, the World Health Organization reports that Hepatitis E infects approximately 20 million people annually, causing 3.4 million illnesses, 70,000 deaths, and 3,000 stillbirths. In India, it remains a major health problem, contributing up to 40% of all acute hepatitis cases and 15-45% of acute liver failure cases. The WHO has previously approved a Hepatitis E vaccine under its International Coordinating Group (ICG) mechanism.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.